• 00Days
  • 00Hrs
  • 00Mins
Join mailing list
anzchog2023-logo-website-md

Partners

The 2023 ANZCHOG Annual Scientific Meeting is the premier event for the Australia and New Zealand Children’s Haematology/ Oncology Group. Bringing together more than 250 members of the industry including paediatric oncologists, haematologists, nurses, allied and mental health professionals, research scientists, clinical research professionals, and parents, to discuss the latest developments in research and treatment. 

The event will cover the latest in research and development and industry news. Don’t miss the opportunity to be part of that conversation! 

Diamond Partner
Diamond Partner, Exhibitor
Jazz Pharmaceuticals
Gold Partner
ANZCHOG - Sponsors (500x500) (12)
Servier
Silver Partner
RCD Foundation
International Speaker Sponsor
Child Cancer Research Foundation
Exhibitors
Diamond Partner, Exhibitor
BD
Jazz Pharmaceuticals
Recordati Rare Diseases
View Online Prospectus

Applications for partnership

Show your support for the Annual Scientific Meeting 2023 by becoming a partner or exhibitor. 

For all partnership or exhibition enquiries, please contact:

c/o MCI Australia 
Thomas Howden 
ANZCHOG ASM Partnership Manager 

ORGANISER

MCI Australia
Level 11, 87 Wickham Terrace
Spring Hill QLD 4000

P: +61 7 3858 5400

E: info@asm-anzchog.com

STAY IN TOUCH
Join mailing list
Privacy Policy | Designed and built by MCI Australia

© 2023 ASM. All rights reserved.

Bayer is a global life science company with expertise in healthcare and agriculture. The company has had a presence in Australia since 1925 and has a long-term commitment to the health and nutrition of all Australians and New Zealanders. As people live longer and the population continues to grow both locally and beyond, Bayer is one of the few companies that takes a comprehensive view of these issues. Guided by our purpose – Science for a better life – we apply our global scientific expertise in healthcare and agriculture to deliver innovations locally to help people and the planet thrive.

Bayer employs almost 900 people across Australia and New Zealand and is dedicated to servicing the needs of rural and remote communities. Bayer embraces and encourages its employees’ unique identities and advances a culture of inclusion and diversity across gender, LGBTQIA+, generations, disability and race.

For further information visit www.bayer.com.au

At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), our purpose is to innovate to transform the lives of patients and their families.

We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.

We are a fully integrated, global biopharmaceutical company with a diverse portfolio of marketed medicines and novel product candidates for adults and children, and expertise in two key therapeutic areas: neuroscience and oncology. We are an industry leader in treating sleep disorders and epilepsy, and in oncology we are investigating and delivering medicines for hard-to-treat hematologic malignancies and solid tumors. We use our deep knowledge of and commitment to these fields to innovate and identify new solutions where none previously existed.

At Recordati Rare Diseases, we focus on the few – those affected by rare diseases. We believe that every single patient has the right to the best possible treatment. Patients with rare diseases are our top priority. They are at the core of our planning, our thinking and our actions.

Recordati Rare Diseases is a pharmaceutical company that provides treatment for patients with rare diseases. Created in 1990, Recordati Rare Diseases is one of the most active companies in the field of rare diseases.

Our speciality rate disease products are marketed directly by Recordati Rare Diseases in Europe, the Middle East, the U.S.A, Canada, Russia, Japan and Australia, in some Latin American countries, and through selected partners in other parts of the world.

We’re all about changing the odds of paediatric brain cancer, to make brain tumours go the way of the dinosaurs. This is why we we fund brain projects in the areas of research, care and development – to fund the science to end brain cancer and support patients in the meantime.

The creation of the Foundation was inspired by nine year old Jennifer Harper, who was diagnosed with leukaemia in 1977. When her father, Peter Harper, discovered that there was no research into children’s leukaemia being done in Western Australia, he set out, together with other parents of children with cancer, to raise funds for this purpose. Sadly Jennifer passed away in 1978.

The quest to find cures for childhood cancer is one of medicine’s greatest success stories. Fifty years ago only two percent of children with cancer survived. Medical research alone has improved overall survival rates to 80 percent. With childhood cancer still the leading cause of death from disease in Australian children, there is more work to be done. There are still particular childhood cancers – such as brain tumours and neuroblastoma — with survival rates as low as 50 percent.

CCRF has a commitment to ensure this ground-breaking research continues so that the future generations will be the ones to live cancer free. The Foundation relies on the generous support of the community to continue its vital research, as we do not receive State or Federal funding.

BD is a global medical technology company that is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes.

Becton Dickinson Pty. Ltd., an Australian subsidiary company, commenced operations in Melbourne in 1981. In October 1996, Becton Dickinson Limited (New Zealand) was established to demonstrate the company’s total commitment to servicing both the Australian and New Zealand markets. BD has a strong presence across its three core businesses in Australia and New Zealand with its Head Office in Sydney and with offices in Auckland, Melbourne, Brisbane, Perth and Adelaide.

Join the ASM mailing list

Stay informed about the latest updates. This can include speakers, abstract submission information, program updates, and other important updates. 

* indicates required

Established in Europe in 1906, Norgine Pty Limited was first incorporated in Australia in 1973 although Norgine’s products were available through local sales agents well before that time.

The business, based at our headquarters in Frenchs Forest in the northern suburbs of Sydney, is a service provider for its Dutch parent Norgine B.V. regarding the Australian- and New Zealand markets. Norgine B.V. has provided a range of pharmaceutical products for a variety of conditions. We have gradually expanded over the years and seen sales rise. Norgine is now in the top 50 pharmaceutical companies in the country.

Website update

Abstracts now open

View Abstract guidelines and make a submission via the Abstract page

Important dates

  • Submissions open: Now
  • Submissions close: May 2023
  • Notifications of successful abstracts: June 2023

21 March, 2023